MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia.

Trial Profile

MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms MABTENANCE
  • Most Recent Events

    • 16 Feb 2018 The study has been completed in Bulgarian (End Date:2017-11-28) according to European Clinical Trials Database.
    • 05 Feb 2018 The study has been completed in Slovakia (End Date:2017-11-28).
    • 15 Jan 2018 The study has been completed in Austria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top